PCSK9 Inhibition

Single Infusion Gene Editing Lowers LDL by Up to 62% in Early Trial

NEJM‑published interim Heart‑2 data won FDA Fast Track designation, prompting Eli Lilly to plan a Phase 2 study later this year.